{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:49:18Z","timestamp":1785235758820,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Melanoma is widely recognized as the most aggressive and fatal type of skin cancer; however, effective prognostic markers are lacking. The sialic acid-binding immunoglobulin-type lectin (Siglec) gene family plays an important role in the development of tumors and immune escape, but its prognostic role in melanoma remains unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Siglec genes have a high mutation frequency, with up to 8% in SIGLEC7. High expression levels of Siglecs in tumor bulk suggests a better prognosis. Siglecs also show a high degree of synergistic expression. Immunohistochemistry was used to analyze the expression of SIGLEC9 in tumor tissue microarray. The expression of SIGLEC9 in tumor tissue without metastasis was higher than that in tumor tissue with metastasis. We used unsupervised clustering to create a high expression of Siglec (HES) cluster and a low expression of Siglec (LES) cluster. The HES cluster correlated with high overall survival and increased expression levels of Siglec genes. The HES cluster also showed significant immune cell infiltration and activation of immune signaling pathways. We used least absolute shrinkage and selection operator (LASSO) regression analysis to reduce the dimensionality of Siglec cluster-related genes and constructed a prognostic model composed of SRGN and GBP4, which can risk-stratify patients in both the training and test datasets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conducted a multi-omics analysis of the Siglec family genes in melanoma and found that Siglecs play an important role in the occurrence and development of melanoma. Typing constructed using Siglecs can show risk stratification and derived prognostic models can predict a patient\u2019s risk score. In summary, Siglec family genes are potential targets for melanoma treatment as well as prognostic markers that can direct individualized treatments and improve overall survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1036019","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:24:31Z","timestamp":1683091471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-omics analysis of Siglec family genes in cutaneous melanoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Kezhu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-102419-035900","article-title":"Siglecs as immune cell checkpoints in disease","volume":"38","author":"Duan","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res:  Off J Am Assoc Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40259-013-0016-7","article-title":"Targeting CD22 in b-cell malignancies: current status and clinical outlook","volume":"27","author":"Sullivan-Chang","year":"2013","journal-title":"BioDrugs: Clin Immunotherapeut Biopharmaceut Gene Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0158-1","article-title":"Developmental therapeutics in acute myelogenous leukemia: Are there any new effective cytotoxic chemotherapeutic agents out there","volume":"8","author":"Mims","year":"2013","journal-title":"Curr Hematol Malignancy Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Software"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: Gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21352","article-title":"State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now","volume":"66","author":"Tripp","year":"2016","journal-title":"CA: A Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"128500","DOI":"10.1016\/j.bmcl.2021.128500","article-title":"Metabolic installation of macrophage-recruiting glycan ligand on tumor cell surface for in vivo tumor suppression","volume":"57","author":"Xie","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.48916","article-title":"Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis","volume":"8","author":"Singh","year":"2019","journal-title":"eLife"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1328","article-title":"SCS macrophages suppress melanoma by restricting tumor-derived vesicle-b cell interactions","volume":"352","author":"Pucci","year":"2016","journal-title":"Sci (New York NY)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0180","article-title":"Prognostic significance of CD169+ lymph node sinus macrophages in patients with malignant melanoma","volume":"3","author":"Saito","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1038\/s41598-020-71216-2","article-title":"The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression","volume":"10","author":"Choi","year":"2020","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0505","article-title":"Siglec-9 regulates an effector memory CD8 T-cell subset that congregates in the melanoma tumor microenvironment","volume":"7","author":"Haas","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-02948-9","article-title":"Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma","volume":"478","author":"Qu","year":"2021","journal-title":"Virchows Archiv:  Int J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8306","article-title":"Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.06.014","article-title":"The \"-OMICS\" facet of melanoma: heterogeneity of genomic, proteomic and metabolomic biomarkers","volume":"59","author":"Donnelly","year":"2019","journal-title":"Semin Cancer Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1036019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:24:35Z","timestamp":1683091475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1036019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2023.1036019"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1036019","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1036019"}}